INTRODUCTION
Asthma is the most common chronic disease of childhood and the leading cause of childhood morbidity from chronic disease as measured by school absences, emergency department visits, and hospitalizations 1 . Asthma typically begins in early childhood, with an earlier onset in males than females [3] [4] [5] . Atopy is present in the majority of children with asthma over the age of 3, and allergen-specific sensitization is one of the most important risk factors for the development of asthma 6 . However, no intervention has yet been shown to prevent the development of asthma or to modify the long-term natural course of the disease.
Asthma is defined as a chronic inflammatory disorder of the airways and is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing 7 . However, in children 5 years and younger, the clinical symptoms of asthma are variable and non-specific. Furthermore, neither airflow limitation nor airway inflammation, the main pathologic hallmarks of the condition, can be assessed routinely in this age group. For this reason, to aid in the diagnosis of asthma in young children, a symptoms-only descriptive approach that includes the definition of various wheezing phenotypes has been recommended 2 .
For all patients with a confirmed diagnosis of asthma, the goal of treatment is to achieve control of the clinical manifestations of the disease, and maintain this control for prolonged periods, with appropriate regard to the safety and cost of the treatment required to achieve this goal. Control of asthma can be achieved in a majority of children 5 years and younger with a pharmacologic intervention strategy developed in partnership between the family/caregiver and the health care practitioner. As in older children and adults, inhaled therapy constitutes the cornerstone of asthma treatment in children 5 years and younger.
Methodology
Recommendations are made based on the best evidence currently available, and are intended to serve as an initial reference point with the recognition that some recommendations may need to avoidance for the treatment of established asthma 10 . Moreover, there is no evidence that antihouse dust mite measures prevent the onset of asthma [11] [12] [13] .
Companion animal allergens:
The relationship between exposure and sensitization to allergens from companion animals is not clear, and there are insufficent data to recommend for, or against, the presence of a pet in the home unless the child has become sensitized to the pet species 8, [14] [15] [16] .
Cockroaches: Exposure to cockroach allergen in the living quarters is associated with the development of sensitization, and sensitization to cockroach allergen is associated with an increased risk of developing asthma 17 .
Fungi: Sensitization to Alternaria is a major risk factor not only for the development of asthma in children, but also for its severity 18, 19 . Alternaria is usually considered an outdoor aeroallergen, but outdoor and indoor concentrations may be similar 20 .
Maternal Diet During Pregnancy and/or Lactation
At present, there are insufficient data to support a protective effect of any dietary intervention during pregnancy or lactation in preventing asthma or atopic disease 21, 22 . Breastfeeding itself decreases early childhood wheezing syndromes associated with upper and lower respiratory infections. However, although recommended for its general health benefits, there is little evidence that breastfeeding prevents development of persistent asthma 9, [23] [24] [25] .
Pollutants
Maternal smoking during pregnancy and exposure to environmental tobacco smoke early in life are associated with a greater risk of developing wheezing illnesses in childhood 26 , as well as with reduced lung function later in life 5 . Therefore, every effort should be made to avoid exposing children to tobacco smoke 27 .
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Use of biomass fuels in the home has been associated with an increased risk of asthma, increased severity of asthma, and exercise-induced bronchospasm in children 28, 29 . This presents a problem in much of the world where biomass fuels such as wood, charcoal, animal dung, and crop residues are used on a daily basis for cooking and/or heating. Outdoor air pollution related to traffic has been shown to trigger wheezing in the first 3 years of life 30 .
Microbes And Their Products
Wheezing in early childhood is predominately linked to viral infections, especially those due to rhinovirus, respiratory synctial virus (RSV), Boca virus, and metapneumovirus (MPV) [31] [32] [33] .
The impact of bacterial products and their relationship to the development of asthma is increasingly a focus of interest and forms part of the so-called "hygiene hypothesis." Exposure to a farming environment in early life has been associated with a reduced risk of asthma and allergy in children compared to those who have not grown up on a farm 34, 35 . In this regard, exposure to the lipopolysaccaride endotoxin from microorganisms encountered in the farming environment appears to be a potential protective factor, particularly in children with specific genetic polymorphisms 36 .
Since intestinal flora are the largest source of microbial exposure for most infants and children, the use of probiotics to modify the composition of intestinal flora has been proposed as a method for exploiting this asthma-protective effect of microbes. While probiotics have been shown to be of some benefit in the prevention of atopic dermatitis, no impact on the development of asthma has been demonstrated 37 .
Although the use of antibiotics also modifies the composition of intestinal flora, the impact of use of antibiotics early in life on the risk of developing asthma later in life is controversial 38, 39 .
Based on available data, it is recommended that particularly broad-spectrum antibiotics should be used with circumspection in this young age group, and only for recognized indications (Evidence D). Stress in family or other primary caregivers during the first year of life is associated with an atopic profile and wheeze in infants, and is also associated with asthma at age 6 to 8 years 42 .
Psychosocial Factors
Maternal distress in early life may play a role in the development of childhood asthma, especially if the distress continues beyond the postpartum period 43 .
Other Risk Factors
Children born by Cesarean section have a higher risk of asthma than those born by vaginal delivery 44 , particularly children of allergic parents 45 . Paracetamol (acetaminophen) use during pregnancy 46 and for fever in the child's first year of life 47 have been associated with increased prevalence of asthma in children.
Summary
Since the contributions of different risk factors to the development of asthma vary widely in different societies and homes, their relative importance overall may be difficult to assess.
Avoidance of some risk factors requires societal and public health interventions. However, measures to avoid other risk factors can be implemented by individual concerned parents as part of their personal preventive strategies for asthma, and these include:
• Avoid exposures to atmospheric pollution and particularly tobacco smoke
• Avoid unnecessary use of antibiotics in young children
• Provide a calm and nurturing environment (Evidence D)
DIAGNOSIS
Making a diagnosis of asthma in children 5 years and younger may be difficult because episodic respiratory symptoms such as wheezing and cough are also common in children who do not have asthma, particularly in those younger than 3 years 48, 49 . Furthermore, it is not possible to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Clinical History
For children 5 years and younger with a history of recurrent respiratory symptoms; a strong family history of asthma in first degree relatives (especially the mother); and/or atopy presenting as atopic dermatitis, food allergy, and/or allergic rhinitis also make a diagnosis of asthma more likely.
Tests for Diagnosis
While no tests diagnose asthma with certainty in young children, the following may be considered as useful adjuncts in making a diagnostic decision. Tests for Atopy: Sensitization to allergens can be assessed using either immediate hypersensitivity skin testing or an in vitro method that detects antigen-specific IgE antibody.
Skin-prick testing is less reliable for confirming atopy in infants.
Chest Radiograph (X-ray): If there is doubt about the diagnosis of asthma in a wheezing child, a plain chest radiograph may help to exclude structural abnormalities of the airway (e.g., congenital malformations such as congenital lobar emphysema, vascular ring), chronic infection (e.g. tuberculosis), or other diagnoses.
Lung function testing, bronchial challenge, and other physiological tests do not have a major role in the diagnosis of asthma in children 5 years and younger due to the inability of children this age to perform reproducible expiratory maneuvers. Such tests are only possible in specialized centers, and are undertaken mainly for research purposes.
Differential Diagnosis
Although a variety of tools have been described above to aid the clinician in making a diagnosis of asthma in children 5 years and younger, it must be emphasized that a definite diagnosis in this young age group is challenging and has important clinical consequences. Thus, alternative causes that can lead to respiratory symptoms of wheeze, cough, and breathlessness must be considered and excluded before an asthma diagnosis is arrived at 48 ( Table 1) . 
Wheezing Phenotypes
Recurrent wheezing occurs in a large proportion of children five years and younger. However, not all of this wheezing indicates asthma. Several phenotypes of wheezing disorders in this age group have been recognized in epidemiologic studies.
Early childhood wheezing has been classified by a Task Group convened by the European Respiratory Society (ERS) 2 as either episodic wheeze (wheezing during discrete time periods, often in association with clinical evidence of a common cold, with absence of wheeze between episodes) or multiple-trigger wheeze (wheezing that occurs as episodic exacerbations as above, but also with symptoms including cough and wheeze occurring between these episodes, during sleep or with triggers such as activity, laughing, or crying).
Data from a U.S. cohort study 5 led to the description of three wheezing phenotypes: transient wheeze (symptoms begin and end before the age of 3 years), persistent wheeze (symptoms begin before the age of 3 years and continue beyond the age of 6 years), and late-onset wheeze (symptoms begin after the age of 3 years).
The clinical usefulness of the phenotypes described by the ERS Task Group 2 or based on data from the U.S. cohort study 5 remains a subject of active investigation. Children with asthma may To aid in the early identification, in the clinical setting, of children 5 years and younger who wheeze and are at high risk of developing persistent asthma symptoms, a number of risk profiles have been evaluated [53] [54] [55] [56] . One such predictive assessment, the Asthma Predictive Index (API), is recommended for children with four or more wheezing episodes in a year and is based on information obtained from the Tucson (USA) Respiratory Study 54 . One study has shown that a child with a positive API has a 4-to 10-fold greater chance of developing asthma between the ages of 6 and 13, while 95% of children with a negative API remained free of asthma 54, 56 . The applicability and validation of the API in other countries and clinical situations is awaited.
MANAGEMENT AND PHARMACOLOGIC TREATMENT
Asthma Education
Asthma education should be provided to family members and caregivers of wheezy children 5 years and younger when wheeze is suspected to be caused by asthma. An educational package should contain a basic explanation about asthma and the factors that influence it, instruction about correct inhalation technique and the importance of adherence to the prescribed medication regime, and a description of how to recognize when asthma control is deteriorating and the 
Asthma Control
For all patients with a confirmed diagnosis of asthma, the goal of treatment is to achieve control of the clinical manifestations of the disease and maintain this control for prolonged periods, with appropriate regard to the safety and cost of the treatment required to achieve this goal.
The relevance of distinguishing between current control (as assessed by the control or elimination of clinical features of asthma in the recent weeks or months) from "future risk" (the likelihood of future worsening, exacerbations, impaired lung development), and the relationship between these two concepts, have not been carefully studied in small children. However, a combination of increased daytime cough, daytime wheeze, and nighttime β 2 -agonist use has been found to be a strong predictor of an exacerbation in children 5 years and younger (predicting around 70% of exacerbations, with a low false positive rate of 14% 59 ). In contrast, no individual symptom was predictive of an imminent asthma exacerbation. This finding indirectly supports the importance of good daily asthma control and the use of composite outcomes in the assessment of asthma control in this age group.
Although exacerbations may occur in children after months of apparent clinical control, the risk is greater in patients whose current control is poor. On the other hand, the "future risk" of harm caused by excessive doses of medications, or inappropriate treatment such as the prolonged use of high doses of inhaled or systemic glucocorticosteroids, must also be avoided by ensuring that 60 ).
However, a working scheme based on current expert opinion presents characteristics of controlled, partly controlled, and uncontrolled asthma for children 5 years and younger based on
(1) symptoms recognized by family members/caregivers and (2) the child's need for reliever/rescue treatment ( Table 2 ) (Evidence D).. 
Pharmacotherapy
Inhaled therapy constitutes the cornerstone of asthma treatment in children 5 years and younger.
A general strategy for choosing inhalers in children is provided in Table 3 . A pressurized metered-dose inhaler (MDI) with a valved spacer (with or without a face mask, depending on the child's age) is the preferred delivery system 61 (Evidence A). This recommendation is based on studies with performed with β 2 -agonists.
Spacers come in different designs and, since the dose received may vary considerably from one device to another, a spacer device that has documented efficacy in young children is recommended. Nebulizers, the only viable alternative delivery systems in children, should be reserved for the minority of children who cannot be taught effective use of a spacer device. for the pharmacologic treatment of asthma in children 5 years and younger. 63, 67 .
In the daily clinic inhaled glucocorticosteroids was reported to reduce hospitalizations (mainly because of less readmissions in children younger than 24 months) 74 . Use of inhaled glucocorticosteroids for up to 2 years has not been documented to induce remission of asthma; symptoms almost always return when treatment is stopped 56 (Evidence B).
Safety:
The majority of studies evaluating the systemic effects of inhaled glucocorticosteroids have been undertaken in children older than 5 years. However, the available data in children 5 years and younger suggest that, as in older children, clinically effective doses of inhaled glucocorticosteroids are safe and the potential risks are well balanced by the clinical benefits 56, 62, 72 . Generally, low doses of inhaled glucocorticosteroids ( . Montelukast has also been shown to reduce airway hyperresponsiveness to methacholine 77 or hyperventilation with cold dry air 80 . A randomized, placebo-controlled trial of the addition of montelukast to usual asthma therapy among 42 children aged 2-5 81 found that this treatment reduced the number of days with worsening of asthma symptoms in boys but not in girls, the number of days with symptoms in the two groups being 7.8% and 3.5%, respectively. In summary, leukotriene modifiers improve some asthma outcomes in young children (Evidence A). However, the role of leukotriene modifiers as add-on therapy in children 5 years and younger whose asthma is uncontrolled on inhaled glucocorticosteroids has not been specifically evaluated.
Safety: No safety concerns have been demonstrated from the use of leukotriene modifiers in young children.
Theophylline
Although a few studies in children 5 years and younger suggest clinical benefit from regular use of theophylline, the effects are small and mostly non-significant 82 . The efficacy of theophylline is less than that of low-dose inhaled glucocorticosteroids, and side effects are more common (Evidence D). 
Long-acting inhaled ß 2 -agonists

Cromolyn and nedocromil sodium
A Cochrane Review concluded that there was no beneficial effect of cromolyn therapy in preschool children 84, 85 (Evidence A) and nedocromil has not been studied in preschool children.
Therefore, cromones cannot be recommended in this age group.
Oral and systemic glucocorticosteroids
Because of the side effects associated with prolonged use, oral glucocorticosteroids in young children with asthma should be restricted to the treatment of acute severe exacerbations, whether
viral-induced or otherwise (Evidence D).
Immunotherapy
No studies of immunotherapy for asthma have been performed in this age group. Therefore, immunotherapy is not recommended for the treatment or prophylaxis of asthma in children 5 years and younger (Evidence D). 
Comparisons Between Controller Medications
Inhaled glucocorticosteroids and cromolyn
In older children and adults, regular treatment with inhaled glucocorticosteroids has been well documented to be clinically more effective than other controller treatments for asthma.
Moreover, they attenuate the decline in lung function seen in association with severe exacerbations 86 . Fewer comparative studies have been conducted in children 5 years and younger. However two studies of nearly 1,000 children in this age group 87, 88 confirmed the superiority of inhaled glucocorticosteroids over cromones for almost all endpoints assessing asthma control (Evidence A).
Inhaled glucocorticosteroids and leukotriene modifiers
Two studies have compared inhaled glucocorticosteroids with leukotriene modifiers. A oneyear, randomized, open study compared montelukast with nebulized budesonide in 400 children;
overall measures favored budesonide 89 . In a blinded, placebo-controlled study of 63 children, fluticasone propionate treatment significantly improved symptoms over placebo, whereas montelukast did not, and fluticasone propionate also improved lung function after three months 90 (Evidence B).
Inhaled glucocorticosteroids and demand bronchodilator/glucocorticosteroid combination
Another study reported that regular inhaled glucocorticosteroid was more effective than on demand treatment with a bronchodilator/glucocorticosteroid combination in children aged 1-4 years with frequent wheeze 91 .
Reliever Medications
Rapid-acting inhaled ß 2 -agonists are the most effective bronchodilators available and therefore the preferred reliever treatment for asthma in children 5 years and younger. An MDI with spacer is, in most cases, an effective way for delivering reliever therapy 61, 92 (Evidence A). When delivery is not optimal because of lack of cooperation or distress, or when the child is hypoxic, There is no evidence that inhaled ipratropium has an important role in the daily management of asthma in children 5 years and younger 93 (Evidence A).
Treatment Strategy
The goal of asthma treatment, to achieve and maintain control of the disease, can be reached in a majority of children 5 years and younger with a pharmacologic intervention strategy 87 developed in partnership between the family/caregiver and the health care practitioner. Although validated tools for assessment of asthma control have not been developed for young children, it is recommended that both current impairment (day and night symptoms, activity level impairment, need for rescue medications) and future risk (likelihood of acute exacerbation in the future) be assessed and controlled ( Table 2 ) (Evidence B).
Who Should be Treated
Regular controller treatment is normally recommended for children 5 years and younger whose frequency and severity of asthma symptoms without treatment indicates that their asthma is not controlled ( Table 2) .
Selecting Initial Therapy
A low-dose inhaled glucocorticosteroid is recommended as the preferred initial treatment to control asthma in children 5 years and younger 56, 69, 89 (Table 4 ) (Evidence A). This initial treatment should be given for at least 3 months to establish its effectiveness in reaching control. If at the end of this period the low dose of inhaled glucocorticosteroid does not control symptoms, and the child is using optimal technique and is adherent to therapy, doubling the initial dose of glucocorticosteroid given in Table 4 may be the best option (Evidence C).
Addition of a leukotriene modifier to the low-dose inhaled glucocorticosteroid may also be considered, although this has not been studied in this age group (Evidence D). Table 5 presents a management approach based on asthma control for children 5 years and younger. fails to achieve and maintain asthma control, the child's inhalation technique and compliance with the medication regimen should be carefully assessed and monitored, as these are common problems in this age group. Furthermore, control of environmental factors should be assessed and addressed appropriately, and the asthma diagnosis reconsidered.
The best treatment for children whose asthma is not controlled on twice the initial dose of inhaled glucocorticosteroid has not been established. Options to consider are to further increase the dose of inhaled glucocorticosteroid (perhaps combined with more frequent dosing), or to add a leukotriene modifier, theophylline, or a low dose of oral glucocorticosteroid for a few weeks until the control of the child's asthma improves (Evidence D). The need for this additional treatment should be re-evaluated at each visit and maintained for as short a period as possible.
Furthermore, the treatment goal or level of control that is feasible for each child must be considered and discussed with the family/caregivers, since a compromise might be necessaryaccepting a level of persisting symptoms to avoid excessive and harmful doses of oral and inhaled glucocorticosteroids or theophylline.
Duration and Adjustments to Treatment:
Asthma symptoms remit in a substantial proportion of children 5 years and younger, and marked seasonal variations are seen in chronic symptoms and the risk of exacerbations. For children with seasonal symptoms, if daily long-term control therapy is discontinued after the season a written action plan detailing specific signs of worsening asthma, and therapeutic interventions that should be subsequently initiated, should be reviewed with the caregivers. It is recommended that the continued need for asthma treatment in children under age 5 should be regularly assessed (e.g., every three to six months) (Evidence D).
A follow-up visit should be scheduled 3-6 weeks after discontinuation of therapy to ascertain whether the remission of symptoms persists and there is no need for reinstitution of therapy. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Where the diagnosis is in doubt, and when rapid-acting inhaled ß 2 -agonist therapy needs to be repeated more frequently than every 6-8 weeks, a diagnostic trial of regular controller therapy should be considered to confirm whether the symptoms are due to asthma (Evidence D).
The best way to treat intermittent episodic wheezing that occurs in children where a diagnosis of asthma cannot be confirmed, or is unlikely, is controversial. The short-term addition of a controller medication -inhaled glucocorticosteroid, leukotriene modifier, or oral glucocorticosteroid -has demonstrated no effects on wheezing symptoms or progression to asthma [94] [95] [96] [97] [98] [99] [100] [101] [102] . However, in one study treating wheezing episode with 1,500 µg of fluticasone proprionate daily for 10 days reduced the need for oral glucocorticosteroids for the episode (18% in the untreated arm versus 8% in the treated arm) 103 . Therefore, although these treatments are widely practiced, based on current evidence, their continued use cannot be recommended (Evidence D).
Acute Exacerbations
The management of acute exacerbations of asthma in children 5 years and younger includes an action plan to enable the child's family members and caregivers to recognize an asthma attack and initiate treatment, recognize a severe episode, identify when urgent hospitalized treatment is necessary, and provide specific recommendations for follow-up (Evidence D).
Definition
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John Wiley & Sons, Inc. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w 25 An acute exacerbation of asthma in children 5 years and younger is defined as an acute or subacute deterioration in symptom control that is sufficient to cause distress or risk to health necessitating a visit to a health care provider or requiring treatment with systemic glucocorticosteroids 104 . Early symptoms of an acute exacerbation may include any of the following :
Pediatric Pulmonology
• An increase in wheeze and shortness of breath
• An increase in coughing, especially nocturnal cough
• Lethargy or reduced exercise tolerance
• Impairment of daily activities, including feeding
• A poor response to reliever medication
Upper respiratory symptoms frequently precede the onset of an asthma exacerbation, indicating the important role of upper respiratory tract viral infections in precipitating exacerbations in many, although not all, asthmatic children.
Home Action Plan for Family/Caregivers
An asthma action plan should be considered for use by the family/caregivers of children 5 years and younger (Evidence D). Developed through collaboration between an asthma educator, the health care provider, and the family, action plans have been shown to be of value in older children [105] [106] [107] [108] , although they have not been sufficiently studied in this younger age group. An asthma action plan should contain details that will enable those who care for the child to recognize exacerbations early, and know what interventions are required, including when medical help should be sought. The home action plan should also provide details (including telephone numbers) of services available for emergencies -doctors' offices, emergency rooms and hospitals, ambulance services, and, where relevant, emergency pharmacies. Treatments that can be initiated at home are inhaled rapid-acting β 2 -agonist and oral glucocorticosteroids, but specific instructions on their use must be provided in the action plan. of inhaled rapid-acting β 2 -agonist, given one puff at a time via a mask or spacer device (Evidence D). The child should be observed by the family/caregiver and maintained in a restful and reassuring atmosphere for an hour or more. Medical attention should be sought the same day if the inhaled bronchodilator is required for symptom relief more than every 3 hours or for more than 24 hours.
Need for urgent medical attention. Immediate medical attention should be sought:
• For children younger than 1 year requiring repeated rapid-acting inhaled ß 2 -agonists over the course of hours
• If the child is acutely distressed
• If the symptoms are not relieved promptly by inhaled bronchodilator
• If the period of relief after a dose of inhaled ß 2 -agonist becomes progressively shorter 109 Family/Caregiver Initiated Oral Glucocorticosteroids. Although practiced in some parts of the world, the evidence to support the initiation of oral glucocorticosteroid treatment by family/caregivers in the home management of asthma exacerbations in children is weak, and should be considered only where the physician is confident that they will be used appropriately (Evidence D).
Assessment of Severity
Features that indicate that an exacerbation is severe are provided in Table 6 
Indications for Hospitalization
Indications for hospitalization of children 5 years and younger are presented in Table 7 .
Children with features of a severe exacerbation that fail to resolve in 1 to 2 hours in spite of repeated dosing with rapid-acting inhaled ß 2 -agonists, with or without the addition of oral glucocorticosteroids, must be referred for observation and further treatment in the hospital (Evidence D). Other indications are respiratory arrest or impending arrest, lack of supervision in the home or emergency department, and recurrence of signs of severity within 48 hours of the initial exacerbation (particularly if treatment with systemic glucocorticosteroids has been given).
In addition, early medical attention should be sought in children under 2 years of age where the risk of dehydration and respiratory fatigue is increased. • No response to three (3) administrations of an inhaled short-acting β 2 -agonist within 1-2 hours
• Tachypnea (Normal respiratory rate < 60 breaths per minute in children 0 -2 months; < 50 in children 2-12 months; < 40 in children 1 -5 years) despite 3 administrations of an inhaled • Child is unable to speak or drink or is breathless
• Cyanosis
• Subcostal retractions
• Oxygen saturation when breathing room air < 92%
• Social environment that impairs delivery of acute treatment; caregivers unable to manage acute asthma at home
Emergency Treatment and Pharmacotherapy
Treat hypoxemia: The presence of hypoxemia must be treated urgently with oxygen delivered by face mask, to achieve and maintain percutaneous oxygen saturation above 94% (Evidence A).
A 24% facemask is usually adequate with oxygen flow set to manufacturer's instructions (usually 4 L per minute). To avoid hypoxemia during changes in treatment, children who are acutely distressed should be treated immediately with oxygen and rapid-acting bronchodilator (2.5 mg of salbutamol or equivalent diluted in 3 ml of sterile normal saline) delivered by an oxygen-driven nebulizer (if available). This treatment should not be delayed, and may be given before the full assessment is completed.
Bronchodilator therapy: The initial dose of rapid-acting bronchodilator may be given by oxygen-driven nebulizer (as described above), or if hypoxemia is absent (or an oxygen-driven nebulizer not available) by either an air-driven nebulizer or a pressurized MDI with spacer and mask or mouthpiece. For most children, the MDI plus spacer is favored as it is more efficient than the nebulizer 61, 110, 111 (Evidence A) for bronchodilator delivery. The initial dose is two puffs of salbutamol (100 µg per puff) or equivalent. A dose of 2.5 mg salbutamol solution is recommended when a nebulizer is used. The frequency of dosing depends on the response observed over 1 to 4 hours (see below).
Inhaled glucocorticosteroids or leukotriene modifier:
Children who have been prescribed maintenance therapy with inhaled glucocorticosteroids, leukotriene modifier, or both should continue to take the prescribed dose during and after an exacerbation (Evidence D). 
Assessment of Treatment Response
Children with a severe exacerbation must be observed for at least 1 hour after initiation of treatment, at which time further treatment can be planned.
• If symptoms persist, a further 2 puffs of salbutamol may be given 20 minutes after the first dose and repeated at 20-minute intervals for an hour. Failure to respond to this at 1 hour, or earlier if the child deteriorates, should prompt urgent admission to the hospital and a short course of oral glucocorticosteroids (Evidence D).
• If symptoms improve at 1 hour, but recur within 3 or 4 hours, more frequent doses of bronchodilator may be given (2 or 3 puffs hourly), and oral glucocorticosteroids should be administered. The child should be observed by the family/caregiver and might need to remain in the emergency room or have ready access to emergency care. Children who fail to respond to 10 puffs of inhaled rapid acting β 2 -agonist should be referred to the hospital (Evidence D).
• If the symptoms resolve rapidly and do not recur for 1 or 2 hours, no further treatment might be required. The dose of bronchodilator may be repeated every 3 to 4 hours (up to a total of 10 puffs per 24 hours) and, if symptoms persist beyond 1 day, other treatments including inhaled or oral glucocorticosteroids are indicated (Evidence D).
Additional Treatment
When treatment in addition to short-acting bronchodilators is required for an exacerbation, the options available for children this age include inhaled glucocorticosteroids (if not already used, short-term or long-term, either nebulized or administered via a pressurized MDI), a short course of oral glucocorticosteroid, and leukotriene modifiers. Although such interventions have been shown to result in statistically significant benefits in several studies, their clinical benefit, particularly on such endpoints as hospitalizations and longer-term outcomes, have not been impressive [95] [96] [97] [98] [99] [100] [101] [102] 112 . The exception to this pattern is one study of 1,500 µg of fluticasone Regardless of the type of intervention, with either glucocorticosteroids or leukotriene modifiers, the severity of symptoms at the time the therapy is initiated must be carefully monitored. The sooner therapy is started in relationship to the onset of symptoms, the more likely the impending exacerbation may be clinically attenuated or abated. Table 8 provides a summary of management of acute severe asthma in children 5 years and younger. 
Follow-up of Exacerbations
Children who have recently had an asthma exacerbation are at risk of further episodes and require follow-up to ensure complete recovery, to establish the cause of the exacerbation, and, o The bronchodilator should be used on an as-needed basis, but the daily requirement should be recorded to assure it is being decreased over time to preexacerbation levels o Initiate or continued inhaled glucocorticosteroids (for first month after discharge, 3 times low initial dose, then adjust dose as needed) Before discharge, the condition of the patient should stable, e.g., out of bed and able to eat and drink without problem.
Summary: Key Messages
1. The goal of asthma treatment, to achieve and maintain control of the disease, can be reached in a majority of children 5 years and younger with a pharmacologic intervention strategy developed in partnership between the family/caregiver and the health care practitioner.
2. Maternal smoking during pregnancy and exposure to environmental tobacco smoke early in life are associated with a greater risk of developing wheezing illnesses in childhood, as well as with reduced lung function later in life. Therefore, every effort should be made to avoid exposing children to tobacco smoke.
3. Making a diagnosis of asthma in children 5 years and younger may be difficult because episodic respiratory symptoms such as wheezing and cough are also common in children who do not have asthma, particularly in those younger than 3 years.
4. A diagnosis of asthma in young children can often be made based largely on symptom patterns and on a careful clinical assessment of family history and physical findings. The presence of atopy or allergic sensitization provides additional predictive support, as early allergic sensitization increases the likelihood that a wheezing child will have asthma.
5. Asthma education should be provided to family members and caregivers of wheezy children 5 years and younger when wheeze is suspected to be caused by asthma.
6. For all patients with a confirmed diagnosis of asthma, the goal of treatment is to achieve control of the clinical manifestations of the disease and maintain this control for prolonged periods, with appropriate regard to the safety and cost of the treatment required to achieve this goal.
7. The prolonged use of high doses of inhaled or systemic glucocorticosteroids must be avoided by ensuring that treatment is appropriate and reduced to the lowest level that maintains satisfactory current clinical control.
8. A pressurized metered-dose inhaler (MDI) with a valved spacer (with or without a face mask, depending on the child's age) is the preferred delivery system. 10. Because of the side effects associated with prolonged use, oral glucocorticosteroids in young children with asthma should be restricted to the treatment of acute severe exacerbations, whether viral-induced or otherwise.
11. Rapid-acting inhaled ß 2 -agonists are the most effective bronchodilators available and therefore the preferred reliever treatment for asthma in children 5 years and younger.
12. A low-dose inhaled glucocorticosteroid is recommended as the preferred initial treatment to control asthma in children 5 years and younger.
13. If low dose of inhaled glucocorticosteroid does not control symptoms, and the child is using optimal technique and is adherent to therapy, doubling the initial dose of glucocorticosteroid may be the best option.
14. When doubling the initial dose of inhaled glucocorticosteroids fails to achieve and maintain asthma control, the child's inhalation technique and compliance with the medication regimen should be carefully assessed and monitored, as these are common problems in this age group.
15. Continued need for asthma treatment in children under age 5 should be regularly assessed (e.g., every three to six months). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
